CSL -1.9%: biotech giant leads healthcare selloff on global rotation away from defensive quality
CSL Limited fell $7.35 to $382.61, its second consecutive down session, as global investors rotated from high-multiple healthcare and biotech into hardware-adjacent AI plays and financials. As Australia's largest company by market cap, CSL's decline disproportionately weights the MSCI Australia index. With no company-specific catalyst, the move appears macro-driven—mirroring GSK and Unilever declines in the UK.